Allogene Therapeutics, Inc. (ALLO) Tops Q2 EPS by 4c

Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q2 EPS of ($0.23), $0.04 better than the analyst estimate of ($0.27).

For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.

You May Also Be Interested In

• Vail Resorts (MTN) 2200 contracts October 145 puts trade into quarter results
• Stifel on MongoDB (MDB): 'post today's 18% sell off we believe further near-term downside is likely limited'
• Mirum Pharmaceuticals (MIRM) PT Raised to $144 at Citizens